Brivaracetam

NERVOUS SYSTEM

Key facts

Brivaracetam is an ofp drug catalogued in DrugCentral. It was first approved by the EMA in 2016. Its mechanism of action is classified as Epoxide Hydrolase Inhibitors. DrugCentral lists 2 molecular targets, including SV2A and Sv2a. Recorded indications include Partial seizure.

• Approval status: ofp (first approved 2016 by the EMA).
• Mechanism of action: Epoxide Hydrolase Inhibitors.
• Molecular targets: SV2A and Sv2a (2 listed in DrugCentral).
• Indications: Partial seizure.
• ATC code: N03AX23 (Other antiepileptics).
• Molecular formula: C11H20N2O2; molecular weight 212.29 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Partial seizure

Mechanism & targets

• Mechanism of action (MoA): Epoxide Hydrolase Inhibitors

Molecular targets (2)

Target	Gene	Action	Activity
Synaptic vesicle glycoprotein 2A	SV2A	modulator	Ki 7.10
Synaptic vesicle glycoprotein 2A	Sv2a	inhibitor	IC50 7.00

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2016-02-18	FDA	—	UCB INC
2016-01-14	EMA	—	UCB Pharma SA

ATC classification

ATC code	Therapeutic hierarchy
N03AX23	NERVOUS SYSTEM › ANTIEPILEPTICS › ANTIEPILEPTICS › Other antiepileptics

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: CYP2C19 · Informative PGx
• FDA label: CYP2C19 · Actionable PGx
• HCSC label: CYP2C19 · Informative PGx
• Swissmedic label: CYP2C19, CYP2C9 · Informative PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Seizure	2143.4
Multiple-drug resistance	734.2
Status epilepticus	494.6
Generalised tonic-clonic seizure	463.9
Aggression	364.5
Partial seizures	331.7
Off label use	328.1
Irritability	304.5
Somnolence	281.9
Behaviour disorder	275.0
Drug ineffective	264.8
Overdose	219.1

Chemical structure

• Molecular formula: C₁₁H₂₀N₂O₂
• Molecular weight: 212.29 g/mol
• CAS number: 357336-20-0
• InChIKey: MSYKRHVOOPPJKU-BDAKNGLRSA-N
• PubChem CID: 9837243

CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Brivaracetam used for?

DrugCentral lists the following indications for Brivaracetam: Partial seizure.

How does Brivaracetam work?

Brivaracetam is classified as Epoxide Hydrolase Inhibitors; its molecular targets in DrugCentral include SV2A (modulator) and Sv2a (inhibitor).

When was Brivaracetam first approved?

Brivaracetam was first approved by the EMA in 2016.

What is the chemical formula of Brivaracetam?

Brivaracetam has the molecular formula C11H20N2O2 and a molecular weight of 212.29 g/mol.

Sources

• DrugCentral drug card 5068 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL607400 — compound record and bioactivity
• PubChem CID 9837243 — chemical identifiers
• DrugBank DB05541 — drug record
• FDA UNII U863JGG2IA — substance identity
• DailyMed: FDA labels for Brivaracetam — current prescribing information (label search)
• UniProt Q7L0J3 (SV2A) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.